Horizon Pharma plc extends offer to acquire Depomed, Inc.
Tuesday, October 27, 2015
Horizon Pharma plc, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Depomed, Inc. ("Depomed") to 5 p.m., Eastern time, on November 20, 2015. An extraordinary general meeting of Horizon Pharma's shareholders is scheduled for November 13, 2015, the principal purpose of which is to approve the issuance of Horizon ordinary shares in connection with Horizon Pharma's proposed acquisition of Depomed. Horizon shareholder approval is one of the conditions required to consummate the exchange offer and the exchange offer is being extended until after the Horizon special meeting.
The depositary of the exchange offer has advised that, as of 9:00 a.m., Eastern time, on October 26, 2015, a total of approximately 7,873 shares of Depomed common stock were validly tendered and not properly withdrawn in the exchange offer. The exchange offer was previously scheduled to expire at 5 p.m., Eastern time on November 6, 2015. All other terms and conditions of the exchange offer remain unchanged.
ir.horizon-pharma.com
